AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02134223 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical behavior therapy
Description: in standard DBT, we will employ all treatment modalities: a weekly individual (1 hour) and group (2 hours) session, available telephone consultation, and DBT consultation team.~DBT participants will be assigned to the next available individual therapist and relevant skills training group.~Groups have a minimum of four members before commencement and a maximum of twelve members. Entry to the skills group occurs only at the commencement of the next skills module.
Study NCT02134223 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as Usual: any other drug or psychotherapy offered to participants, except DBT
Study NCT04191473 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EMR-P
Description: After submucosal injection, we use ESD knife or the tip of the entrapment device to loop around the lesion, and then overlapped the loop tangent with the entrapment device. After tightening the entrapment device, all the tumor tissues were confirmed to enter the entrapment device, and the tissues were removed.
Study NCT04191473 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: CEMR
Description: A liquid pad was formed by injecting 0.9% normal saline with meilan solution into submucosa,and then overlapped the loop tangent with the entrapment device. After tightening the entrapment device, all the tumor tissues were confirmed to enter the entrapment device, and the tissues were removed.
Study NCT03801473 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: robot assisted gait therapy
Description: The Robogait is a fixed lower body hip-knee exoskeleton. The user's weight is supported by a combination of an overhead attached harness and the support from the exoskeleton.
Study NCT03801473 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation
Description: Conventional rehabilitation program. Exercise and walking education is performed by the physiotherapists.
Study NCT02170818 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Workshop on Speaking-Up
Description: Educational workshop including lecture, discussion, role-play Concepts include: 2-challenge rule, pairing advocacy and inquiry
Study NCT02170818 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Unrelated Education (CPR)
Description: Unrelated Education (CPR workshop) including: lecture, discussion Topics covered: Cardiac Life Support algorithms, CPR, Medications
Study NCT01321151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: The dose of resveratrol is 500 mg. The route of administration is oral, once-a-day for 30 days after injury.
Study NCT01321151 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is a sugar pill. The route of administration is oral, once-a-day for 30 days after injury.
Study NCT04483700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Match Filgotinib
Description: Tablets administered orally once daily
Study NCT00791063 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 18F ML-10
Description: Patients will undergo 2-3 brain PET/CT sessions; A pre-treatment session and 1-2 sessions post WBRT treatment. Each PET/CT session will be done following intravenous administration of 18F-ML-10, to assess tracer uptake by the tumor.
Study NCT00291616 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated Interferon-alpha2a
Description: 180 microgram s.c. injection weekly
Study NCT00291616 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thymosin alpha1 & Pegylated Interferon-alpha2a
Description: Pegylated interferon 180 microgram s.c. injection weekly Thymosin 1.6 mg s.c. injection twice per week
Study NCT03111303 — intervention group
Intervention type: DEVICE
Intervention: mechanical ventilation
Description: Connection to mechanical ventilator
Study NCT02763306 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermal Cooling System
Description: Treatment with dermal cooling system.
Study NCT02893566 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mi Band Step Challenge
Study NCT04921202 — intervention group
Intervention type: OTHER
Intervention: Metabolic syndrome and meniscus injuries
Description: Metabolic syndrome
Study NCT01575028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: The TAP block will be delivered with 0.2ml/kg of 0.2% Ropivacaine with 1:200,000 epinephrine bilaterally
Study NCT01575028 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: The local anesthetic at the incision sites will be injected by the surgeon.
Study NCT01319708 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mild ovarian stimulation
Description: 100-150 mg of clomiphene citrate from day 2 till day 6 of the cycle and 150 mg of gonadotrophins as soon as 1 follicle is more than 14mm together with 1 fixed dose of GnRH antagonist until egg recovery
Study NCT01319708 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional ovarian stimulation
Description: 300-450 IU of FSH starting by day 2 of menstrual cycle together with a fixed dose of GnRH antagonist starting by day 6 till egg recovery, or same doses with GnRH agonist long protocol
Study NCT00002682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Study NCT00002682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth Subsalicylate
Study NCT00002682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Study NCT00002682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole Hydrochloride
Study NCT00002682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Study NCT00002682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracycline Hydrochloride
Study NCT03525444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-445/TEZ/IVA
Description: Participants received VX-445/TEZ/IVA orally once daily in the morning.
Study NCT03525444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: Participants received IVA orally once daily in the evening
Study NCT03525444 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received placebo matched VX-445/TEZ/IVA orally once daily in the morning and placebo matched to IVA orally once daily in the evening.
Study NCT03033277 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo transplantation
Description: Intraovarian injection of placebo through vagina under the guidance of ultrasonic.
Study NCT03033277 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HUC-MSCs transplantation
Description: Intraovarian injection of HUC-MSCs through vagina under the guidance of ultrasonic.
Study NCT03460886 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ipsilesional stimulation
Description: anodal stimulation on Ipsilesional leg area of primary motor cortex and supplementary motor area for 30 minutes
Study NCT03460886 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contralesional stimulation
Description: anodal stimulation on contralesional leg area of primary motor cortex and supplementary motor area for 30 minutes
Study NCT03460886 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking on treadmill
Description: walking on treadmill for 10 minutes
Study NCT03460886 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Walking on treadmill
Description: walking on treadmill for 10 minutes
Study NCT03270943 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MFY
Description: Mindful Self-Compassion course for teens
Study NCT03270943 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HLG
Description: Healthy Lifestyles course for teens
Study NCT02973100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dulaglutide
Description: Administered SC
Study NCT02973100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: Administered SC
Study NCT02973100 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT03285724 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Harpoon Artificial ePTFE Chords
Description: The Harpoon Medical Transapical device is intended to be used to reduce the degree of degenerative mitral regurgitation by delivering and anchoring one or more ePTFE cords to the affected mitral valve leaflet(s) via a small left thoracotomy on the beating heart in patients with anterior, bi-leaflet or posterior prolapse.
Study NCT01590030 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic dermoid cystectomy
Description: Laparoscopy will be performed by pneumoperitoneum with CO2. A complete pelvic examination will be performed to exclude malignant disease. Ovarian capsule will be incised by scissors on mesial side in study group and antimesial side in control group. After cleavage plane identification the cyst enucleation will be completed by atraumatic dissection.
Study NCT01590030 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic dermoid cystectomy
Description: Laparoscopy will be performed by pneumoperitoneum with CO2. A complete pelvic examination will be performed to exclude malignant disease. Ovarian capsule will be incised by scissors on mesial side in study group and antimesial side in control group. After cleavage plane identification the cyst enucleation will be completed by atraumatic dissection.
Study NCT00055302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arimidex 1 mg
Description: Arimidex (anastrozole) 1mg once daily by mouth
Study NCT04032067 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GV1001 placebo
Description: 0.9 % Normal Saline
Study NCT04032067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proscar placebo
Description: PO
Study NCT02861612 — intervention group
Intervention type: PROCEDURE
Intervention: Nerve Transfer Surgery
Description: Unilateral surgery will be performed under general non-paralytic anesthesia and no-tourniquet conditions to allow for responsive nerve simulation.
Study NCT04483700 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Match Filgotinib
Description: Tablets administered orally once daily
Study NCT00214279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid withdrawal
Description: prednisone withdrawal, with maintenance mycophenolate mofetil therapy and either cyclosporine or tacrolimus
Study NCT00678067 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid
Description: Soft capsules 500 mg/each; 1 capsule/day for 4 months
Study NCT00678067 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA)+ Eicosapentaenoic acid (EPA)
Description: Soft capsules, 228 mg DHA + 208 mg EPA /each; 1 capsule/day for 4 months
Study NCT00678067 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Germ oil
Description: Soft capsules, 275 mg linoleic acid + 35 mg linolenic acid + 65 mg oleic acid /each; 1 capsule/day for 4 months
Study NCT03618368 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THERANOVA-500 dialyzer
Description: THERANOVA-500 dialyzer is a hemofilter that enables Expanded Hemodialysis (HDx) therapy.
Study NCT03901170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5mg
Description: oral administration of letrozole 2.5mg/tab, 1tab once per day from stimulation Day 7 to hCG Day.
Study NCT00937352 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bapineuzumab
Description: 0.5 mg/kg, administered via IV (in the vein) infusion every 13 weeks for 4 years.~1.0 mg/kg, administered via IV (in the vein) infusion every 13 weeks for 4 years.
Study NCT03070288 — intervention group
Intervention type: OTHER
Intervention: Red-green-blue measurements of nasal mucosa image
Description: Adobe Photoshop Elements 7.0 program automatically measures the numerical values of the RGB color components in the selected area
Study NCT01517750 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ICON Auto CPAP™ with Thermosmart heated tube
Description: ICON Auto CPAP™ with heated humidification and the use of a heated tube
Study NCT01517750 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ICON Auto CPAP™ without Thermosmart heated tube
Description: ICON Auto CPAP™ without heated humidification or the use of a heated tube.
Study NCT01298479 — intervention group
Intervention type: OTHER
Intervention: Uniject
Description: single use container
Study NCT02534376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezetimibe 10mg-simvastatin 40mg
Description: Vytorin (ezetimibe 10mg-simvastatin 40mg) will be given on an outpatient basis. The drug will be taken orally each day until the subject undergoes radical prostatectomy. The start of Vytorin is timed so that patients get the last dose the day before surgery. Subjects receive a two to four weeks of Vytorin.
Study NCT01716286 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: low fat vs. essence yoghurt
Study NCT02099240 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral antibiotics
Description: intravenous antibiotics with early switch to oral antibiotics, antibiotic type will be dependent on bacteria type
Study NCT02099240 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intravenous antibiotics
Description: intravenous antibiotics for the full duration of therapy, antibiotic type will be dependent on bacteria type
Study NCT00678067 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: National Cholesterol Education Program (NCEP) Step I Diet
Description: Dietary counselling aimed at achieving NCEP Dietary Guidelines: Total fat intake \<30% of total calories, Saturated fat intake \<10% of total calories, Polyunsaturated fat intake up to 10% of total calories, monounsaturated fat intake 10-15% of total calories
Study NCT00678067 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: National Cholesterol Education Program (NCEP) Step I Diet
Description: Dietary counselling aimed at achieving NCEP Dietary Guidelines: Total fat intake \<30% of total calories, Saturated fat intake \<10% of total calories, Polyunsaturated fat intake up to 10% of total calories, monounsaturated fat intake 10-15% of total calories
Study NCT01141725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine hydrochloride
Description: Given IV
Study NCT01141725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin
Description: Given IV
Study NCT02717247 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tRNS
Description: The intervention consists in active tRNS stimulation with cathode above the left dorsolateral prefrontal cortex (DLPFC) which corresponds to the F3 location given by the 10-20 system. Anode is above the right dorsolateral prefrontal cortex (F4).~100Hz-650Hz, 2mA, 30min, twice daily, 5 days
Study NCT02717247 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tRNS
Description: The intervention consists in placebo or sham tRNS stimulation electrode are above F3 and F4. Voltage will be ramped at the begin and end of a stimulation for 30 seconds. Placebo stimulation will consist of just applying the ramps at the begin and end of the stimulation.
Study NCT04725084 — intervention group
Intervention type: OTHER
Intervention: Use of High Flow Nasal Cannula alone
Description: Use of high flow nasal cannula oxygen therapy alone
Study NCT04725084 — intervention group
Intervention type: OTHER
Intervention: Use of Non-invasive Ventilation
Description: Use of non-invasive ventilation combined or not with high flow nasal cannula oxygen therapy
Study NCT04725084 — intervention group
Intervention type: OTHER
Intervention: Use of Continuous Positive Airway Pressure
Description: Use of continuous positive airway pressure combined or not with high flow nasal cannula oxygen therapy
Study NCT00028665 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Beginning 36-48 hours after the completion of cyclophosphamide, patients receive filgrastim (G-CSF) subcutaneously (SC) daily until blood counts recover. Patients receive G-CSF SC daily beginning 4 hours after completion of PBSC infusion and continuing until neutrophil engraftment.
Study NCT00028665 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: filgrastim
Description: Beginning 36-48 hours after the completion of cyclophosphamide, patients receive filgrastim (G-CSF) subcutaneously (SC) daily until blood counts recover. Patients receive G-CSF SC daily beginning 4 hours after completion of PBSC infusion and continuing until neutrophil engraftment.
Study NCT00028665 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: rituximab IV over 2-5 hours on days 1, 8, and 15
Study NCT00028665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine
Description: After completion of PBSC collection, patients receive high-dose chemotherapy comprising carmustine IV on days -7 to -3
Study NCT00028665 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carmustine
Description: After completion of PBSC collection, patients receive high-dose chemotherapy comprising carmustine IV on days -7 to -3
Study NCT00028665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: After completion of PBSC collection, cisplatin IV for 3 days during days -7 to -3.
Study NCT03618368 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: REVACLEAR-400 dialyzer
Description: REVACLEAR-400 dialyzer is an usual hemofilter that enables conventional hemodialysis (HD).
Study NCT00307502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine
Description: tablets 200 mg, 400 mg/day
Study NCT00307502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: tablets 600 mg, 600 mg/day
Study NCT00307502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indinavir/ritonavir
Description: Indinavir: capsules 400 mg, 1600 mg/day~Ritonavir: capsules 100 mg, 200 mg/day
Study NCT00307502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelfinavir
Description: tablets 250 mg, 2500 mg/day
Study NCT00307502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saquinavir/ritonavir
Description: Saquinavir: tablets 500 mg, 2000 mg/day~Ritonavir: tablets 100 mg, 200 mg/day
Study NCT00307502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Description: tablets lopinavir 200 mg + ritonavir 50 mg, 800/200 mg/day
Study NCT00307502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir
Description: capsules 200 mg, 400 mg/day
Study NCT00307502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir
Description: Atazanavir: capsules 150 mg, 300 mg/day~Ritonavir: capsules 100 mg, 200 mg/day
Study NCT00307502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fos-amprenavir/ritonavir
Description: Fos-amprenavir: capsules 700 mg, 1400 mg/day~Ritonavir: capsules 100 mg, 200 mg/day
Study NCT02257593 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary protein
Description: Persons were fed~Participants were randomized to one of three arms, each of which received 10%, 15% or 25% of total energy derived from protein
Study NCT04123886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCB-313
Description: SCB-313 Intrapleural injection, once daily. Single dose on Day 1 in Cycle 0 followed by 7-day safety assessment, then dose on Day 1,2,3 in Cycle 1 followed by 21-day observation .
Study NCT01391364 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SofLens in investigational solution
Description: SofLens in investigational solution, worn on a daily disposable basis for 7 days.
Study NCT01391364 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SofLens in currently marketed solution
Description: SofLens packaged in currently marketed solution, worn on a daily disposable basis for 7 days.
Study NCT00668421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEP-701 (Lestaurtinib)
Description: Lestaurtinib (CEP-701), oral formulation. Phase 1: 80 BID - 160 BID; phase 2: 140 mg
Study NCT02122835 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: aerobic exercise training
Description: 12 weeks of supervised aerobic exercise training
Study NCT02249806 — intervention group
Intervention type: OTHER
Intervention: PH target therapy according to physician
Description: Patients receiving PH target therapy
Study NCT01777035 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: early PT OT
Description: 1. Passive range of motion (ROM) in pts who remain unresponsive despite sedative interruption.~2. active assisted ROM in supine position.~3. treatment is advanced to bed mobility activities~4. sitting balance activities followed by participation in activities of daily living (ADLs) and exercises that encourage increased independence with functional tasks.~5. progression to transfer training, and finally pre-gait training and ambulation.~6. progression of activities dependent on patient tolerance and stability~7. therapy sessions continue on a daily basis throughout hospital stay until return to prior level of function or is discharged.